AUB ScholarWorks

New treatment developments applied to elderly patients with advanced prostate cancer

Show simple item record

dc.contributor.author Mukherji D.
dc.contributor.author Pezaro C.J.
dc.contributor.author Shamseddine A.
dc.contributor.author De Bono J.S.
dc.contributor.editor
dc.date Oct-2013
dc.date.accessioned 2017-10-05T15:40:13Z
dc.date.available 2017-10-05T15:40:13Z
dc.date.issued 2013
dc.identifier 10.1016/j.ctrv.2012.12.004
dc.identifier.isbn
dc.identifier.issn 03057372
dc.identifier.uri http://hdl.handle.net/10938/17310
dc.description.abstract Prostate cancer is a common disease amongst elderly men. Compared with younger patients, men over the age of 75 are more likely to present with advanced disease and have a greater risk of death from prostate cancer despite higher death rates from competing causes. Treatment options for advanced prostate cancer have improved considerably in the last two years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope radium-223 and the antiandrogen enzalutamide have all been shown to improve survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. This review will focus on the clinical data regarding new treatment developments specifically applied to elderly patients with advanced prostate cancer. © 2012 .
dc.format.extent
dc.format.extent Pages: (578-583)
dc.language English
dc.publisher OXFORD
dc.relation.ispartof Publication Name: Cancer Treatment Reviews; Publication Year: 2013; Volume: 39; no. 6; Pages: (578-583);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title New treatment developments applied to elderly patients with advanced prostate cancer
dc.type Review
dc.contributor.affiliation Mukherji, D., Department of Hematology-Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon
dc.contributor.affiliation Pezaro, C.J., Prostate Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM25PT, United Kingdom
dc.contributor.affiliation Shamseddine, A., Department of Hematology-Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon
dc.contributor.affiliation De Bono, J.S., Prostate Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM25PT, United Kingdom
dc.contributor.authorAddress Mukherji, D.; Department of Hematology-Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon; email: Dm25@aub.edu.lb
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology;
dc.contributor.authorDepartment Internal Medicine
dc.contributor.authorDivision Hematology-Oncology
dc.contributor.authorEmail Dm25@aub.edu.lb; Carmel.pezaro@icr.ac.uk; As04@aub.edu.lb; johann.de-bono@icr.ac.uk
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Mukherji, D
dc.contributor.authorInitials Pezaro, CJ
dc.contributor.authorInitials Shamseddine, A
dc.contributor.authorInitials De Bono, JS
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Mukherji, D (reprint author), Amer Univ Beirut, Med Ctr, Dept Hematol Oncol, POB 11-0236, Beirut 11072020, Lebanon.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Armstrong AJ, 2011, J CLIN ONCOL S7, V29; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200-JCO.2007.15.9749; Aventis S, 2011, JEVTANA PRESCRIBING; Bahl A, 2012, J CLIN ONCOL S5, V30, P44; BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016-0960-0760(94)90131-7; Basch E, 2012, J CLIN ONCOL; Bok Robert A., 1999, Drug Safety, V20, P451, DOI 10.2165-00002018-199920050-00005; Dall'era MA, 2012, EUR UROL; Danila DC, 2010, J CLIN ONCOL, V28, P1496, DOI 10.1200-JCO.2009.25.9259; de Bono J, 2012, J CLIN ONCOL S, V30; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016-S0140-6736(10)61389-X; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056-NEJMoa1014618; Dendreon, 2011, PROV PRESCR INF; Droz JP, 2010, BJU INT, V106, P462, DOI 10.1111-j.1464-410X.2010.09334.x; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016-S0140-6736(10)62344-6; Heidenreich A, 2012, EUR UROL; Higano CS, 2009, CANCER, V115, P3670, DOI 10.1002-cncr.24429; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322-caac.20073, 10.1002-caac.20073]; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056-NEJMoa1001294; La Vecchia C, 2010, ANN ONCOL, V21, P1323, DOI 10.1093-annonc-mdp530; Longo DL, 2010, NEW ENGL J MED, V363, P479, DOI 10.1056-NEJMe1006300; LUTHY IA, 1988, J STEROID BIOCHEM, V31, P845, DOI 10.1016-0022-4731(88)90295-6; Marbury T, 2011, EUR J CANCER, V47, pS502; Mita AC, 2009, CLIN CANCER RES, V15, P723, DOI 10.1158-1078-0432.CCR-08-0596; Parker C., 2011, EUR MULT CANC C 2011; Pezaro CJ, 2012, J CLIN ONCOL, V30; POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021-jm00013a022; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200-JCO.2009.24.6819; Ryan CJ, 2011, CLIN CANCER RES, V17, P4854, DOI 10.1158-1078-0432.CCR-11-0815; Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200-JCO.2009.24.1281; Ryan CJ, 2012, N ENGL J MED; Saad F, 2002, J NATL CANCER I, V94, P1458; Saad F, 2007, CANCER, V110, P1860, DOI 10.1002-cncr.22991; Saad F, 2012, J CLIN ONCOL S, V30; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016-S0140-6736(10)60172-9; Scher HI, 2011, J CLIN ONCOL S, V29; Scher HI, 2012, N ENGL J MED; Scosyrev E, 2012, CANCER-AM CANCER SOC, V118, P3062, DOI 10.1002-cncr.26392; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056-NEJMoa041943; Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056-NEJMoa0809003; Snedecor SJ, 2011, J CLIN ONCOL S, V29; Sternberg CN, 2011, EUR J CANCER, V47, pS488; Sundar S, 2012, BMJ CASE REP, V2012; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126-science.1168175
dc.description.citedCount 3
dc.description.citedTotWOSCount 4
dc.description.citedWOSCount 4
dc.format.extentCount 6
dc.identifier.articleNo
dc.identifier.coden CTRED
dc.identifier.pubmedID 23290885
dc.identifier.scopusID 84878937422
dc.identifier.url
dc.publisher.address THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Cancer Treat. Rev.
dc.relation.ispartOfIssue 6
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Cancer Treatment Reviews
dc.relation.ispartofPubTitleAbbr Cancer Treat. Rev.
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 39
dc.source.ID WOS:000321317200004
dc.type.publication Journal
dc.subject.otherAuthKeyword Abiraterone
dc.subject.otherAuthKeyword Alpharadin
dc.subject.otherAuthKeyword Cabazitaxel
dc.subject.otherAuthKeyword Castration resistant prostate cancer
dc.subject.otherAuthKeyword CRPC
dc.subject.otherAuthKeyword Denosumab
dc.subject.otherAuthKeyword Elderly
dc.subject.otherAuthKeyword Enzalutamide
dc.subject.otherAuthKeyword Sipuleucel-T
dc.subject.otherChemCAS abiraterone, 154229-19-3
dc.subject.otherChemCAS abiraterone acetate, 154229-18-2
dc.subject.otherChemCAS cabazitaxel, 183133-96-2
dc.subject.otherChemCAS denosumab, 615258-40-7
dc.subject.otherChemCAS docetaxel, 114977-28-5
dc.subject.otherChemCAS enzalutamide, 915087-33-1
dc.subject.otherChemCAS mitoxantrone, 65271-80-9, 70476-82-3
dc.subject.otherChemCAS prednisolone, 50-24-8
dc.subject.otherChemCAS prednisone, 53-03-2
dc.subject.otherChemCAS sipuleucel T, 917381-47-6
dc.subject.otherChemCAS zoledronic acid, 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7
dc.subject.otherChemCAS Antineoplastic Agents, Hormonal
dc.subject.otherIndex abiraterone
dc.subject.otherIndex abiraterone acetate
dc.subject.otherIndex cabazitaxel
dc.subject.otherIndex denosumab
dc.subject.otherIndex docetaxel
dc.subject.otherIndex enzalutamide
dc.subject.otherIndex mitoxantrone
dc.subject.otherIndex placebo
dc.subject.otherIndex prednisolone
dc.subject.otherIndex prednisone
dc.subject.otherIndex prostate specific antigen
dc.subject.otherIndex radium chloride ra 223
dc.subject.otherIndex sipuleucel T
dc.subject.otherIndex zoledronic acid
dc.subject.otherIndex advanced cancer
dc.subject.otherIndex androgen deprivation therapy
dc.subject.otherIndex asthenia
dc.subject.otherIndex blood pressure monitoring
dc.subject.otherIndex bone density
dc.subject.otherIndex bone metastasis
dc.subject.otherIndex cancer chemotherapy
dc.subject.otherIndex castration resistant prostate cancer
dc.subject.otherIndex cell proliferation
dc.subject.otherIndex chill
dc.subject.otherIndex clinical trial (topic)
dc.subject.otherIndex dehydration
dc.subject.otherIndex dizziness
dc.subject.otherIndex drug cost
dc.subject.otherIndex drug efficacy
dc.subject.otherIndex drug excretion
dc.subject.otherIndex drug fatality
dc.subject.otherIndex drug fever
dc.subject.otherIndex drug induced headache
dc.subject.otherIndex drug metabolism
dc.subject.otherIndex drug safety
dc.subject.otherIndex drug tolerability
dc.subject.otherIndex edema
dc.subject.otherIndex elderly care
dc.subject.otherIndex fatigue
dc.subject.otherIndex febrile neutropenia
dc.subject.otherIndex fluid retention
dc.subject.otherIndex heart disease
dc.subject.otherIndex human
dc.subject.otherIndex hypertension
dc.subject.otherIndex hypocalcemia
dc.subject.otherIndex hypokalemia
dc.subject.otherIndex kidney failure
dc.subject.otherIndex metastasis
dc.subject.otherIndex neutropenia
dc.subject.otherIndex osteoclast
dc.subject.otherIndex overall survival
dc.subject.otherIndex pain
dc.subject.otherIndex progression free survival
dc.subject.otherIndex prostate cancer
dc.subject.otherIndex quality of life
dc.subject.otherIndex review
dc.subject.otherIndex seizure
dc.subject.otherIndex sepsis
dc.subject.otherIndex side effect
dc.subject.otherIndex spine fracture
dc.subject.otherIndex treatment response
dc.subject.otherIndex urinary tract infection
dc.subject.otherIndex visual analog scale
dc.subject.otherIndex Aged
dc.subject.otherIndex Aged, 80 and over
dc.subject.otherIndex Antineoplastic Agents, Hormonal
dc.subject.otherIndex Antineoplastic Combined Chemotherapy Protocols
dc.subject.otherIndex Humans
dc.subject.otherIndex Immunotherapy
dc.subject.otherIndex Male
dc.subject.otherIndex Prostatic Neoplasms
dc.subject.otherKeywordPlus INHIBITOR ABIRATERONE ACETATE
dc.subject.otherKeywordPlus I CLINICAL-TRIAL
dc.subject.otherKeywordPlus PHASE-I
dc.subject.otherKeywordPlus STEROIDAL INHIBITORS
dc.subject.otherKeywordPlus ANDROGEN-DEPRIVATION
dc.subject.otherKeywordPlus ANTITUMOR-ACTIVITY
dc.subject.otherKeywordPlus POST-DOCETAXEL
dc.subject.otherKeywordPlus SIPULEUCEL-T
dc.subject.otherKeywordPlus THERAPY
dc.subject.otherKeywordPlus CYP17
dc.subject.otherWOS Oncology


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account